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ABSTRACT: Human islet amyloid polypeptide (hIAPP or
Amylin) is a 37 residue hormone that is cosecreted with
insulin from the pancreatic islets. The aggregation of hIAPP
plays a role in the progression of type 2 diabetes and
contributes to the failure of islet cell grafts. Despite
considerable effort, little is known about the mode of action
of IAPP amyloid inhibitors, and this has limited rational drug
design. Insulin is one of the most potent inhibitors of hIAPP
fibril formation, but its inhibition mechanism is not under-
stood. In this study, the aggregation of mixtures of hIAPP with
insulin, as well as with the separate A and B chains of insulin, were characterized using ion mobility spectrometry-based mass
spectrometry and atomic force microscopy. Insulin and the insulin B chain target the hIAPP monomer in its compact isoform
and shift the equilibrium away from its extended isoform, an aggregation-prone conformation, and thus inhibit hIAPP from
forming β-sheets and subsequently amyloid fibrils. All-atom molecular modeling supports these conclusions.
■ INTRODUCTION
Type 2 diabetes (T2D) is a complex disease that is reaching
epidemic proportions in the developed world.1 Affected
individuals develop insulin resistance and progression of the
disease is associated with a loss of β-cell mass. Human islet
amyloid polypeptide (hIAPP, also known as amylin) forms islet
amyloid in T2D. Evidence is increasing that soluble oligomers
of hIAPP are involved in important aspects of T2D,2−4
including β-cell death,3,5,6 and contribute to the failure of islet
graft transplants.7−9 Thus, islet amyloid, or the process of its
formation, plays a crucial role in the pathology of the disease.10
While the mechanism of hIAPP induced β-cell toxicity is not
fully understood, a range of mechanisms have been proposed
and are likely to be involved in vivo. These include receptor
mediated mechanisms, the triggering of localized inflammatory
response and possibly IAPP induced membrane damage as well
as other mechanisms.10−14
In contrast, monomer hIAPP is soluble and functions as a
partner to insulin in glucose regulation in healthy individuals.15
Insulin and IAPP are coregulated at the expression level, with
both genes having a common promoter.16 In healthy β-cells
IAPP:insulin levels are maintained at about 1:100; however, in
T2D patients this ratio can increase to 1:20.17 Both IAPP and
insulin share the same secretory pathway in the β-cells and thus
have ample opportunity to interact. In the secretory granule,
insulin crystallizes into the form of hexamer aggregates
stabilized by two Zn2+ ions.18,19 Typically these crystals occupy
50−90% of the granule volume at an effective concentration of
∼40 mM and form the dense core of the granule. The
remaining granule contents, including hIAPP, occupy the halo
region of the granule peripheral to the dense core. Hence, in
healthy β-cells hIAPP has an intragranule concentration of 0.8−
4.0 mM. In vitro studies have shown that hIAPP rapidly forms
fibrils at a concentration 2 orders of magnitude less than
this.20,21 In vitro cell toxicity studies further show that hIAPP
oligomers induce apoptosis of pancreatic β-cells.22 Hence,
hIAPP aggregation and its cell toxicity are somehow inhibited
in vivo, since hIAPP plaques are not readily detectable in
nondiabetic individuals.10 The lower pH of the granule likely
plays a role, but cannot account for the high solubility of hIAPP
in the intra granule environment.23 Zn(II)-hIAPP interaction
may stabilize the compact soluble hIAPP monomer.24 Another
obvious potential inhibitor is the dominant secretory pathway
species, insulin. Several studies have shown insulin to be one of
the most potent inhibitors of hIAPP fibrillization in
vitro.20,21,25−30 However, little is known about the mechanism
of this crucial inhibition process, and it is not known if insulin
and other protein-based inhibitors target the same conforma-
tion as small molecule inhibitors of hIAPP amyloid formation.
One proposal is that insulin interacts with the growing hIAPP
fibril tip in some unknown fashion.20 Additional support for
insulin interacting with hIAPP fibrils comes from observations
that insulin interacted with preformed hIAPP fibrils attached to
plasmon resonance chips.27 Using either nonamyloidogenic rat
IAPP (rIAPP)31 or IAPP linked to a maltose binding protein,32
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a helix−helix interaction between the helical insulin and the N-
terminal helix of IAPP was suggested to be involved in the
insulin inhibition mechanism. Peptide array mapping studies
have suggested potential interactions between IAPP and insulin
in regions that are known to transiently form helix.26
We have previously used ion mobility-based mass spectrom-
etry (IMS-MS) coupled with all-atom molecular dynamics
(MD) simulations to characterize monomers33 and dimers34 of
human IAPP and rIAPP. We showed that monomeric hIAPP
can adopt multiple conformations in solution, with the two
dominant ones being a helix−coil isoform and an extended β-
hairpin isoform.33 The relative abundance of these two
conformers is strongly dependent on solution pH with helix−
coil dominating in neutral and acidic solutions and the β-
hairpin isoform dominating in basic solution. Of relevance is
the fact that rIAPP does not induce β-cell apoptosis22 and has
much lower tendency to fibrillize in comparison with
hIAPP.35,36 As a consequence, we used rIAPP as a negative
control34 to help identify crucial aspects of hIAPP that lead to
amyloid and possibly contribute to T2D. The rat peptide does
not form amyloid under the conditions of our assays. The two
peptides are identical at 31 of the 37 amino acid locations with
the 6 differences occurring in the 18−29 region. Of most
importance, rIAPP contains prolines at positions 25, 28, and 29
where hIAPP has Ala, Ser and Ser, and consequently rIAPP
does not form amyloid, but does populate a helix−coil
monomer isoform that is similar to the conformer formed by
the human peptide, and a dominant compact helix−coil
dimer.34 In contrast, the cross section of the hIAPP dimer is
10% larger than the rat dimer and simulations argue that it is
composed predominantly of coupled β-hairpins with a β-strand
interface, suggesting that the β-hairpin form of hIAPP
contributes to its early oligomer states.34 In this conformation
the β-strand interface correlates well with the binding “hot-
spots” identified by Kapurniotu and co-workers through
fragment binding affinity analysis.37
Figure 1. Sequence of hIAPP (a) and mass spectra for 20 μM hIAPP at pH 7.4 obtained at 0 (b), 3 (c) and 6 h (d) after sample preparation. Visible
aggregates appeared in the sample solution after 6 h.
Figure 2. Mass spectra of 1:1 mixture of 20 μM hIAPP and 20 μM insulin at pH 7.4 monitored over a period of 22 days. The mixed hIAPP and
insulin complexes are labeled with blue squares. The intensity of the hIAPP monomer peaks (green triangles) with respect to the insulin monomers
(red dots) start to diminish between 17 and 22 days. By the 24th day, the overall intensity of the spectrum had decreased significantly.
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Insulin is composed of a B-chain (IBC) and a smaller A-chain
(IAC) connected by two disulfide bonds. Our strategy is to
investigate the effects of the intact insulin molecule on hIAPP
assembly and then separately study the effects of the isolated
IAC and IBC fragments. The experimental studies are
complemented by all atom molecular dynamics simulations in
order to provide an atomistic level interpretation. The goals of
this study are to provide a mechanism for the inhibition of
hIAPP oligomerization by insulin, to test if insulin targets
different conformations than known small molecule inhibitors,
and to provide a context for beginning to develop the
knowledge required for rational drug design.
■ RESULTS AND DISCUSSION
hIAPP Forms Amyloid but hIAPP/Insulin Mixtures Do
Not. A mass spectrum of pure hIAPP (Figure 1a) at 20 μM at
pH 7.4 in ammonium acetate buffer collected immediately after
preparing the solution is shown in Figure 1b. The peaks are
labeled by z/n, where z is the charge and n is the oligomer
number. The peak near m/z = 1000 is the +4 monomer and the
peak near m/z = 1310 the +3 monomer. Of interest are the
oligomers that are present even at these early times; the +5/2
dimer, +5/3 trimer, 7/4 tetramer and unresolved larger
oligomers near m/z = 2600. The spectra in Figure 1c,d are
from the same solution but acquired 3 and 6 h later. The latter
spectrum is dominated by unresolved oligomers with only a +3
monomer peak discernible. After 6 h, insoluble aggregates are
visible at the bottom of the sample container.
When insulin is added forming a 1:1 hIAPP to insulin ratio at
pH 7.4, very different results are obtained, and no hIAPP
aggregates are detected (Figure 2). The peaks marked by (▲)
are from hIAPP and those by (●) are from insulin (a spectrum
of pure insulin under these conditions is provided in the
Supporting Information (SI), Figure S1). The insulin peaks are
exactly the same as in the pure insulin sample, showing, from
low m/z to high m/z, +4 and +3 monomers, a +5/2 insulin
dimer, a +2 monomer and finally +10 and +9 insulin hexamers.
hIAPP, on the other hand, only shows +3 and +2 monomers,
and importantly the early oligomers are absent. Little change is
observed in the spectrum over the first 17 days, and only a
small loss of hIAPP relative to insulin is detected by day 22.
This is in stark contrast to the behavior of hIAPP by itself at the
same concentration (Figure 1), where very rapid oligomer
formation is observed. Finally, while no hIAPP oligomers are
observed, weak heteroligomers are seen starting immediately
and are designated by the (■) in the day 22 spectrum. When
this region is amplified [hIAPP+insulin]+4, [hIAPP+2insulin]+5
and [hIAPP+3insulin]+8 peaks are identified, but no hetero-
ligomers with more than 1 hIAPP are detected (Figure S2
(SI)).
Insulin rapidly aggregates at pH ≤ 5.5, but only slowly
aggregates at pH 7.4.38,39 This behavior contrasts with hIAPP,
which rapidly aggregates at high pH, but only slowly at low
pH.23 The extra-celluar environments of the islets of
Langerhans (the regions of the pancreas that contain the cells
which produce insulin and hIAPP) are at pH = 7.4, but the pH
of secretory granule is pH 5.5.20 Hence it is of interest to
further examine the behavior of the mixture at pH 5.5 (Figure
S3 (SI)). The mass spectrum of the freshly prepared sample is
very similar to that of the pH 7.4 mixture (Figure 2). However,
after several days, the insulin peaks disappear, then the hIAPP
(+3 and +2) monomer peaks diminish in intensity. After 15
days, very little hIAPP monomer is left in solution, indicating
that almost all of the insulin and hIAPP have been consumed,
and insoluble aggregates are visible at the bottom of the sample
container. For a sample of pure insulin at pH 5.5 under
identical conditions, a similar aggregation pattern was observed
(Figure S4 (SI)): the initial mass spectrum is nearly identical to
the mass spectrum of an insulin sample at pH 7.4 (Figure S1
(SI)). However, after 1 day, the oligomeric peaks begin to
disappear as insulin aggregates and precipitates.
In order to investigate the effects of insulin on the
morphology of the insoluble aggregates, aliquots from the
incubated samples were dried on freshly cleaved mica and
imaged with an atomic force microscope using the protocol
employed in our previous study33 (Figure 3). In the pH 7.4
mixture, where hIAPP is soluble for up to 4 weeks, amorphous
aggregates are observed, lacking the typical amyloid fiber
morphology. In the pH 5.5 mixture, fibrils are observed, and
their dimensions were consistent with our early finding of the
hIAPP fibrils.33 The fibrils are ∼50 nm wide and have an axial
periodicity of 25−40 nm, which is characteristic of the amyloid
fibril twist.40 Gazit and co-workers26 using fluorescence assays
and CD have shown that the insulin B-chain inhibits fibril
formation of hIAPP, but the A-chain does not. They used
peptide arrays to deduce that residues of the 9−20 B-chain
(S9HLVEALYLVCG20) form contacts with the 7−19 sequence
Figure 3. AFM images taken of the incubated hIAPP and insulin 20 μM mixtures. The mixture at pH 7.4 (left) after four-week incubation has no
fibrils but reveals extensive amorphous aggregates. The mixture (right) at pH 5.5 after 10-day incubation reveals formation of fibrils.
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of hIAPP (C7ATQRLANFLVHS19). The B-chain is helical in
the intact insulin molecule, and this region of hIAPP has also
been shown to transiently populate helical ϕ and ψ angles in
vitro at pH 7.4.41,42 Hence, we felt it important to look at the
effects of the A-chain and B-chain on early oligomer assembly
of hIAPP using IMS-MS methods. Mass spectra of a mixture of
1:1 insulin A chain (IAC) with hIAPP (Figure S5 (SI)) and a
mixture of 1:1 insulin B chain (IBC) with hIAPP (Figure S6
(SI)) at pH 7.4 were obtained over the course of several weeks.
In the 1:1 mixture of IBC and hIAPP, a heterogeneous cluster
of [hIAPP and IBC]+4 is observed, while no heterogeneous
clusters are visible in the IAC and hIAPP mixture. Over the
course of 3 weeks, the mass spectrum of the hIAPP and IBC
sample remains almost the same, with only a small decrease in
hIAPP observed relative to IBC. Different behavior is observed
with the sample of hIAPP and IAC; the hIAPP z/n = +4, +3, +2
peaks decrease and disappear after a few days, indicating that
the sample has aggregated. From these time course studies, we
conclude that IBC and full-length insulin interact with hIAPP in
a similar fashion: they stabilize hIAPP for several weeks, and
their monomers form heterogeneous clusters with one hIAPP
monomer. In contrast, IAC does not inhibit hIAPP aggregation
and does not form heteroligomers with hIAPP.
The Cross Section of the IBC-hIAPP Heterodimer: An
Important Modeling Constraint. Gazit and co-workers26
showed that peptide fragments from a helical region of IBC
interact with peptide fragments from the region of hIAPP that
can form a transient helical structure. This suggests that a
helix−helix interaction may be involved in the IBC-hIAPP
interactions and insulin-hIAPP interactions that lead eventually
to fibril inhibition in hIAPP. We address this point in detail
using all atom modeling studies which are described in the next
section. Here we obtain the cross section of the IBC-hIAPP
heterodimer observed in the mass spectrum in Figure S6 (SI).
This cross section will be important in defining the lower
energy heterodimer structures obtained from the modeling
studies.
The arrival time distribution (ATD) for the [IBC+hIAPP]+4
heterodimer is given in the center panel of Figure 4. The ATD
consists of one dominant peak centered near 0.65 ms arrival
time and a weak shoulder to shorter times. This ATD is flanked
on the left by the [nhIAPP]+2n ATD and on the right by the
[nIBC]+2n ATD obtained from the same mass spectrum as the
heterodimer. These are included to firmly identify the peak
assigned as [IBC+hIAPP]+4, as will be demonstrated. The
ATDs across the top panel were obtained at a lower injection
energy (see Materials and Methods section) than those in the
bottom panel. As the energy is increased, the ions experience
transient collisional heating that can lead to dissociation of
higher oligomers into smaller species. For example, the
[nhIAPP]+2n ATD greatly simplifies due to dissociation of
higher order oligomers when the injection energy is increased
to 80 V from 40 V. This allows assignment of the peak near
0.74 ms as the hIAPP+2 monomer and the peak near 0.66 ms as
the (2 hIAPP)+4 dimer. Similar assignments are made for the
IBC+2 monomer and (2 IBC)+4 dimer. Importantly, the ATD
for the [IBC +hIAPP]+4 heterodimer remains almost
unchanged at higher injection energy with only a reduction
of the shorter time shoulder observed. Hence we can
unambiguously make the assignments of 843 Å2 for the (2
IBC)+4 dimer, 893 Å2 for the [IBC+hIAPP]+4 dimer and 969 Å2
for the (2 hIAPP)+4 dimer, cross sections consistent with the
relative increase in size of these dimers (60, 67 and 74 residues,
respectively).
Insulin and the IBC Reduce the Amyloidogenic
Conformer of Monomeric hIAPP. The question arises as
to how IBC and insulin inhibit the hIAPP assembly process.
Both peptides form heterodimers with hIAPP that are in
Figure 4. Arrival time distributions (ATDS) of [nhIAPP]+2n, [IBC+hIAPP]+4 and [nIBC]+2n under two ion injection voltages (40 and 80 V). At the
lower injection voltage: the ATD of [nhIAPP]+2n shows a monomer, dimer, and smaller trimer and tetramer features; the ATD of the [IBC
+hIAPP]+4 shows mainly [IBC+hIAPP]+4 with a cross section of 893 Å2; and the ATD of [nIBC]+2n has monomer with a cross section of 530 Å2 and
dimer with a cross section of 843 Å2 and probably a small amount of trimer at shortest times. At the higher injection voltage: the large oligomers
dissociate, leaving monomer and dimer as dominant species in all cases.
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dynamic equilibrium with the monomers. How does this
process affect the conformer distribution of hIAPP? Using IMS-
MS, ATDs of the +4 human hIAPP monomer were obtained
from three samples at the same instrumental settings: a pure
hIAPP sample, a sample of 1:1 hIAPP and insulin, and a sample
of 1:1 hIAPP and IBC (Figure 5). The ATD of the +4 hIAPP
monomer in the sample of pure hIAPP corresponds to that
previously shown by Dupuis et al:33 the feature on the left has a
cross section of 653 Å2 consistent with a helix−coil structure,
and the feature on the right has a cross section of 770 Å2
consistent with a more extended β-hairpin structure.33
The ATDs of the hIAPP +4 monomer in the three samples
(pure hIAPP, hIAPP and IBC, hIAPP and insulin) all show
these same two peaks, and the cross sections are identical for all
these samples, indicating the presence of at least two sets of
structures, one compact and one more extended. Early REMD
simulations33 suggest that the two ensembles populate the
helix−coil and β-hairpin structure, respectively. However, the
intensity ratios between the two peaks are quite different,
indicating that the relative abundance of the compact and
extended isoforms differ in these samples. For pure hIAPP, the
compact to extended ratio is approximately 3:1. However, in
both of the mixtures (hIAPP:insulin and hIAPP:IBC) the ratio
increases to approximately 10:1, indicating a significant
decrease in the extended isoform. We will come back to this
point in the Conclusions section.
Molecular Modeling: Insight into the Details of the
Amyloid Inhibition Process. The binding interaction
between hIAPP and IBC was modeled from molecular
dynamics (MD) simulations. The starting structures of +4
hIAPP include a β-sheet rich extended conformation and a
helix-rich compact conformation, identified in our previous
computational study33 as well as in works by Reddy et al.43 and
Qiao et al.44 A starting structure for the IBC was obtained from
a long MD simulation (Figure S7 (SI)) initiated from the
conformation extracted from the X-ray solved crystal structure
of insulin (PDB id: 1GUJ). Note that an early NMR study has
shown that isolated IBC adopts a helix-rich conformation in
mixed aqueous organic solution, which is similar to its structure
in intact insulin.41
IBC formed a complex with both hIAPP conformers in the
last half of the simulations (see Figure S9 (SI)). The results
based on the multiple snapshots within the last 100 ns of the
binding simulations are summarized in Figure 6. The complex
with the extended hairpin conformer of hIAPP (modeled as a
hairpin−helix complex) has a calculated collision cross section
of 1085 Å2. In contrast, the complex with the helix-rich
compact conformer of hIAPP (a helix−helix complex) has a
calculated collision cross section of 972 Å2. Thus, the helix−
helix complex is 10% more compact than the helix-hairpin
complex to the relative uncertainty of 1%. In addition MM-
GBSA calculations indicate the helix−helix complex is
significantly more stable than the hairpin−helix complex.
When compared with the experimental data, the model
Figure 5. ATDs of the +4 hIAPP monomer. The ATD on the left is of the +4 hIAPP monomer in a solution of pure hIAPP. The +4 hIAPP
monomer ATD in the middle was acquired from a sample of 1:1 mixture of hIAPP and insulin, and the ATD on the far right was from a sample of
1:1 mixture of hIAPP and IBC. The ATDs in the three samples were acquired at the same instrumental settings at ion injection energy of 40 V. The
large feature on the left in the ATDs corresponds to compact α-helical structures of the +4 hIAPP monomer, while the feature on the right
corresponds to an extended β-hairpin structure previously described by Dupuis et al.24 The relative abundance of the β-hairpin feature is much
smaller in the mixtures of hIAPP with insulin and IBC than it is in the sample of pure hIAPP. All samples are at concentrations of 20 μM and at pH
7.4.
Figure 6. Representative snapshots of the four dimerization
trajectories between +4 hIAPP and IBC. Whereas the N-terminus of
+4 hIAPP is shown by a red ball, the N-terminus of IBC is shown by a
blue ball. Collision cross section and the relative MM-GBSA binding
energy between hIAPP and IBC with reference to the binding energy
of the complex in AC1 are noted.
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helix−helix complex has a cross section 9% above the
experimental cross section of 893 ± 9 Å2, while the model
hairpin−helix is 22% above the experimental value. Given the
higher stability and the closer agreement with the experimental
data, the helix−helix complex rather than the hairpin−helix
complex appears to be the major stable species in the
experiment. The larger value for the cross section from the
calculation (∼9% for the helix−helix dimer) indicates that the
actual packing between hIAPP and IBC is tighter than that
found in the simulations. In order to get better agreement with
experiment, higher level but computational expensive modeling,
such as replica exchange methods would be needed. According
to our modeling the major packing interface is between the
helix (residues 9−18) of hIAPP and the helix (residues 11−19)
of IBC leading to stronger van der Waals interactions than for
the helix/β-hairpin interface. Of importance is the fact this
interface is consistent with the peptide mapping results of Gazit
and co-workers.26 Interestingly, this interface is very similar to
the binding interface between rIAPP and insulin, derived from a
combined NMR and MD study by Wei et al.31 This is not
surprising, because both rIAPP and hIAPP can adopt similar
transient helix-rich conformations and they have the almost
same sequence in the N-terminal region (1−22) differing only
by the H18R substitution.28
The binding between the two hIAPP conformers and the
larger insulin monomer (PDB id: 1GUJ) was also modeled by
MD simulations. A similar binding pattern to that of IBC and
hIAPP was observed (Figure S11 (SI)). The insulin monomer
formed a stable complex with both hIAPP monomer con-
formers and the major binding interaction was between the
insulin B-chain (residues 11−19) and hIAPP (residues 8−18).
This is consistent with our experimental observation that IBC
monomer rather than IAC monomer plays an important role in
interacting with hIAPP. In addition, the calculated binding
energy of the insulin monomer to the helix-rich hIAPP
conformer was significantly stronger than the calculated binding
energy to the hairpin-rich hIAPP conformer based on our MM-
GBSA binding calculations (Figure S11 (SI)). Hence, the
results indicate that insulin forms stable complexes with either
hIAPP conformer, but the binding to the helix-rich conformer
is much stronger than to the hairpin-rich hIAPP conformer.
■ CONCLUSIONS
Insulin stabilizes hIAPP in a monomeric nonamyloidogenic
state in solution at low molar ratios (1:1) for long periods of
time. As long as insulin monomer is stable in solution,
monomeric hIAPP is also stabilized through the formation of
heterogeneous clusters of insulin and hIAPP. A single hIAPP
monomer binds up to three insulin monomers, but no
heterogeneous clusters are observed with more than one
hIAPP monomer. Our IMS-MS study probes inhibition of the
initial steps of hIAPP assembly. As such it does not exclude the
interaction of insulin with larger hIAPP oligomers/profibrils,
which also may have an inhibitory effect on later steps in hIAPP
assembly. It is likely that insulin also interacts with larger hIAPP
oligiomers as insulin inhibits hIAPP at substoichiometric
concentrations.20,25,29,45
Like insulin, IBC monomers also stabilize hIAPP in a
nonaggregating monomer state and form analogous heteroge-
neous clusters of one IBC monomer and one hIAPP monomer.
However, IAC does not stabilize hIAPP monmers, and no
heterogeneous clusters are observed in the mass spectrum of
IAC/hIAPP mixtures. This indicates that the B-chain of insulin
plays the primary role in stabilizing soluble hIAPP, which is
consistent with our MD modeling and with the results of Gazit
and co-workers.26
Ion mobility studies show that the extended structure of
hIAPP is in much smaller abundance relative to the compact
form of hIAPP monomer in the mixtures of hIAPP with insulin
and insulin B chain compared to the pure hIAPP monomer.
This suggests that insulin and IBC interact with hIAPP
monomers, causing either the conversion of the extended
conformation to the more compact structures or there is a
depletion of the ensemble of extended conformations by
binding to insulin. Our modeling, however is consistent with
IBC and insulin forming significantly more stable complexes
with the compact helix-rich conformer of hIAPP than with the
extended β-hairpin structure. This result suggests insulin and
Figure 7. Proposed mechanism by which IBC inhibits hIAPP aggregation via predominantly forming helix/helix hIAPP:IBC complexes. The N-
terminus of hIAPP and IBC is shown by a red and blue ball, respectively. Thick and thin arrows indicate, respectively, high and low reaction rates,
leading to a reduction of the aggregation-prone β-hairpin of hIAPP. Residues 9−14 of hIAPP and 11−19 of IBC are located at the helix−helix
interface (in purple color) of the most stable complex from the simulations (left-bottom).
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IBC monomers sequester hIAPP helix-rich monomers to form
heterogeneous clusters and shift the equilibrium away from the
extended monomer structure and toward the condensed α-
helical monomer structure. A schematic view of this proposed
mechanism is shown in Figure 7. The selective targeting of one
set of conformations by insulin is similar to the effect of certain
small molecule inhibitors of hIAPP that function by targeting
one subset of the ensemble of hIAPP conformations,46
suggesting that this may be a general strategy for inhibiting
hIAPP amyloid formation.
Finally, our modeling results suggest the stabilization of the
heterodimer complexes occur between residues 11 to 19 of IBC
and 8 to 18 of hIAPP, a result consistent with the peptide
mapping study of Gazit and co-workers.26 Hence an excellent
place to initiate a search for hIAPP aggregation inhibitors is in
peptide fragments derived from the S9HLVEALYLVCG20
segment of IBC. A related method has been fruitful in
discovering inhibitors of soluble oligomer formation of Aβ42,
and subsequently its toxicity. Aβ42 is the peptide primarily
responsible for Alzheimer’s disease.47
■ MATERIALS AND METHODS
A full description of the materials and methods is given in the
Supporting Information. Briefly, the hIAPP samples used in this study
were synthesized according to procedures previously described.48,49 A
hIAPP stock solution (1 mM) was prepared in hexafluoro-2-propanol
(HFIP), and then aliquots of the stock were dried, and the peptides
were resuspended in ammonium acetate buffer as previously described
by Dupuis et al.33,34 The bovine insulin (catalog no. I5500) as well as
the separate A and B chains of bovine insulin were purchased from
Sigma-Aldrich and used without further purification. Mass spectra
were recorded on a prototype of the commercially available Synapt
HDMS (Waters-Micromass, Manchester, U.K.) that features a
nanoelectrospray ion source, an ion mobility cell and a high-resolution
time-of-flight mass spectrometer.50 To investigate the effects of insulin
on the morphology of the insoluble aggregates from the samples,
aliquots from the incubated samples were dried on freshly cleaved
mica and imaged with an Asylum Research MFP-3D-SA atomic force
microscope (Asylum Research, Santa Barbara, CA) following our early
protocol.33 Ion mobility measurements were recorded using a custom
built instrument51 with a nanoelectrospray ionization (ESI) source, ion
funnel, ion mobility drift cell and quadrupole mass analyzer. The
AMBER 852 simulation package was used in modeling the complexes
formed by insulin and IBC with hIAPP. The AMBER all-atom point-
charge protein force field, ff9653 with an implicit solvent IGB = 5,54
was used to model the peptides in this study. Recent accomplishments
of this force field combination include both the successful ab initio
folding of α, β, and α/β proteins33,55−58 and the correct character-
ization of interdomain dynamics of a multidomain signal protein.59
Multiple runs of the same experiment and simulation were conducted
to obtain the uncertainty.
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